EBNA-1 antibody (AA 551-641) (AbBy Fluor® 555)

Catalog No. ABIN1397594

Product Details anti-EBNA-1 Antibody (AbBy Fluor® 555)

Target: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Binding Specificity: AA 551-641

Reactivity: Epstein-Barr Virus (EBV), Virus

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EBNA-1 antibody is conjugated to AbBy Fluor® 555

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Cross-Reactivity: Virus

Cross-Reactivity (Details): Epstein Barr Virus

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for EBNA-1

Target: EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))

Alternative Name: EBV Nuclear Antigen (EBNA-1 Products)

Synonyms: EBNA-1 antibody, latency protein antibody, CeHV15gEBNA-1 antibody, EBNA-1 antibody, HHV4tp2_gp36 antibody

Target Type: Viral Protein

Background:

Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,

Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.